RxDoctor Payments Data

Rodney Haltom, PA

Physician Assistant · Houston, TXNPI 1073668943

Payments from drug & device makers

$3,949in general payments, 2019–2025

Across 136 payments — averaging $29.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$808
  • Bristol Myers Squibb$305
  • Novartis$291
  • GSK$265
  • Syndax Pharmaceuticals, Inc.$233
  • Pharmaessentia USA Corporation$227
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,53289%
  • Education$41711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,949 in reported general payments places this provider in the 85th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$25,864
Medicare patients
299
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate103$1,736,190
OjjaaraMomelotinib Dihydrochloride57$1,553,254
SprycelDasatinib57$414,534
VonjoPacritinib Citrate19$400,104
CalquenceAcalabrutinib Maleate14$192,347
VenclextaVenetoclax17$174,734
Imatinib Mesylate40$114,776
PegasysPeginterferon Alfa-2a13$27,135
Hydroxyurea149$3,560
ValacyclovirValacyclovir Hcl52$2,306
Anagrelide Hcl14$1,200
Levofloxacin30$469
Allopurinol44$308
Gabapentin13$201
Tramadol Hcl16$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$185$1,736,190103 claims
GSKOjjaara$265$1,553,25457 claims
AstraZenecaCalquence$85$192,34714 claims
AbbVieVenclexta$120$174,73417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →